Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025
Differential Ceramide Metabolism in Autogenous and Reactive Obsessions: A Biomarker Perspective in OCD.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ozdemir Ebru, Kulacaoglu Filiz, Atakay Mehmet, Salih Bekir, Senol Onur
Аннотация
OBJECTIVE: This study aimed to compare the levels of ceramide pathway metabolites between autogenous and reactive subtypes of patients with obsessive-compulsive disorder (OCD) and healthy controls (HC).
METHODS: Targeted lipid analyses of ceramide C24:1, hydroxy-ceramide (C24:0 and C18:0), sphingomyelin (SM 16:0), and sphingosine-1-phosphate (S1P) were performed in 52 OCD patients and 27 HC. Patients with OCD group were divided into subgroups based on their primary obsessions: autogenous obsession (AO) and reactive obsession (RO). Sphingolipid species of three groups were compared. Serum samples of ceramide pathway metabolites were analysed by liquid chromatography-mass spectrometry.
RESULTS: C18:0 hydroxy-ceramide and S1P levels were significantly higher in patients with OCD than in the HC (p < 0.001). The levels of C24:1 ceramide in the OCD patients with AO were significantly higher than in the OCD patients with RO (p = 0.013) and in the HC group (p < 0.001). In patients with OCD, significant positive correlations were found between C24:1 ceramide levels and C24:0 hydroxy-ceramide levels (r = 0.326, p = 0.019), between C24:0 hydroxy-ceramide levels and C18:0 hydroxy-ceramide (r = 0.569, p < 0.001) and S1P (r = 0.619, p < 0.001), and between C18:0 hydroxy-ceramide levels and S1P (r = 0.652, p < 0.001).
CONCLUSION: The finding of significantly higher C24:1 ceramide levels in OCD patients with AO may be a novel biomarker that highlights the heterogeneous nature of OCD and the specific neurobiological differences between autogenous and reactive subtypes. This study highlights the role of ceramide pathway metabolites in the pathophysiology of OCD and provides new insights into its underlying mechanisms.
METHODS: Targeted lipid analyses of ceramide C24:1, hydroxy-ceramide (C24:0 and C18:0), sphingomyelin (SM 16:0), and sphingosine-1-phosphate (S1P) were performed in 52 OCD patients and 27 HC. Patients with OCD group were divided into subgroups based on their primary obsessions: autogenous obsession (AO) and reactive obsession (RO). Sphingolipid species of three groups were compared. Serum samples of ceramide pathway metabolites were analysed by liquid chromatography-mass spectrometry.
RESULTS: C18:0 hydroxy-ceramide and S1P levels were significantly higher in patients with OCD than in the HC (p < 0.001). The levels of C24:1 ceramide in the OCD patients with AO were significantly higher than in the OCD patients with RO (p = 0.013) and in the HC group (p < 0.001). In patients with OCD, significant positive correlations were found between C24:1 ceramide levels and C24:0 hydroxy-ceramide levels (r = 0.326, p = 0.019), between C24:0 hydroxy-ceramide levels and C18:0 hydroxy-ceramide (r = 0.569, p < 0.001) and S1P (r = 0.619, p < 0.001), and between C18:0 hydroxy-ceramide levels and S1P (r = 0.652, p < 0.001).
CONCLUSION: The finding of significantly higher C24:1 ceramide levels in OCD patients with AO may be a novel biomarker that highlights the heterogeneous nature of OCD and the specific neurobiological differences between autogenous and reactive subtypes. This study highlights the role of ceramide pathway metabolites in the pathophysiology of OCD and provides new insights into its underlying mechanisms.